AURIGENE DISCOVERY TECHNOLOGIE

Business Nature: Research and Development (R&D) / Contract Research Organization (CRO)

Company Overview:

Aurigene Discovery Technologies is a specialized biotechnology company focused on accelerating the discovery and development of novel therapeutic drugs. As a subsidiary of the global pharmaceutical group Dr. Reddy's Laboratories, the Malaysia facility serves as a strategic hub for integrated drug discovery services. The company operates high-end laboratories equipped with advanced technology to support medicinal chemistry, biology, and preclinical development. Its primary mission is to collaborate with global pharmaceutical and biotech partners to advance innovative drug candidates from target validation through to clinical trials.

Classification:

Aurigene Discovery Technologies is neither a traditional manufacturing factory nor a trading company. It is a specialized science-based R&D and service provider. It functions as a Contract Research Organization (CRO) that provides intellectual services, scientific research, and laboratory-based development solutions to the pharmaceutical industry.

Aurigene Discovery Technologies is a specialized contract research organization (CRO) that focuses on drug discovery rather than the sale of off-the-shelf consumer or industrial products. Their offerings are primarily service-based and research-oriented.

The company provides the following services and solutions:

Integrated Drug Discovery Services

This includes target validation, hit identification, lead optimization, and the delivery of preclinical drug candidates.

Medicinal Chemistry Services

The development of small molecule libraries, structure-based drug design, and synthetic chemistry support.

Biology Services

In vitro and in vivo pharmacology, assay development, high-throughput screening, and biomarker identification.

Therapeutic Area Expertise

Research and development support focused on oncology, immunology, inflammation, and metabolic disorders.

Proprietary Platforms

The use of specialized platforms for protein degradation (PROTACs), peptide therapeutics, and covalent inhibitors.

Preclinical Development Support

Assistance with pharmacokinetics (PK), pharmacodynamics (PD), toxicology studies, and regulatory filing support for investigational new drugs (IND).

It is important to note that Aurigene operates as a research partner for pharmaceutical and biotechnology companies, meaning they do not sell retail products but instead provide intellectual property and research outcomes related to new drug candidates.